Share of acquisitions announced since 2020 · by deal count
Therapeutic areas
Timeline
Eli Lilly
30 acquisitions
Cancer
27%
8 deals
Neuroscience & sensory
27%
8 deals
Immunology
20%
6 deals
Obesity & cardiometabolic
13%
4 deals
Infectious disease
10%
3 deals
Delivery
3%
1 deal
Novo Nordisk
9 acquisitions
Obesity & cardiometabolic
56%
5 deals
Discovery & delivery
33%
3 deals
Rare blood disorders
11%
1 deal
2020
2021
2022
2023
2024
2025
2026
2027
Eli Lilly
Disarm Therapeutics · Headquarters: United States · $135M · Oct 2020 · Creating breakthrough therapeutics to treat patients with neurological diseases by preventing axonal degeneration
🇺🇸
Disarm Therapeutics
$135M · Oct 2020
Neuroscience & sensory
Dermira · Headquarters: United States · Oct 2020 · Development-stage biotech company focused on developing and commercializing innovative new therapies in dermatology
🇺🇸
Dermira
Oct 2020
Immunology
Prevail Therapeutics · Headquarters: United States · $1.0B · Jan 2021 · A biotechnology company
🇺🇸
Prevail Therapeutics
$1.0B · Jan 2021
Neuroscience & sensory
Protomer · Headquarters: United States · $1.0B · Jul 2021 · Glucose-responsive protein therapeutics for automated diabetes management
🇺🇸
Protomer
$1.0B · Jul 2021
Obesity & cardiometabolic
Akouos · Headquarters: United States · $610M · Oct 2022 · New biotechnology company focused on restoring and preserving hearing
🇺🇸
Akouos
$610M · Oct 2022
Neuroscience & sensory
DICE Therapeutics · Headquarters: United States · $2.4B · Jun 2023 · Developing transformative medicines for autoimmune and inflammatory diseases
🇺🇸
DICE Therapeutics
$2.4B · Jun 2023
Immunology
Emergence Therapeutics · Headquarters: Germany · Jun 2023 · European biopharmaceutical company developing novel ADC immuno-therapeutics to treat high-unmet need cancers
🇩🇪
Emergence Therapeutics
Jun 2023
Cancer
Versanis Bio · Headquarters: United States · $1.9B · Jul 2023 · This company is developing a new approach to obesity treatment that could have a significant and lasting impact on patients with this condition
🇺🇸
Versanis Bio
$1.9B · Jul 2023
Obesity & cardiometabolic
Sigilon · Headquarters: United States · $310M · Jul 2023 · Biotech company which specializes in creating immune privileged products for unmet clinical needs
🇺🇸
Sigilon
$310M · Jul 2023
Obesity & cardiometabolic
POINT Biopharma · Headquarters: Canada · $1.4B · Oct 2023 · Developing next-generation radioligand therapies for the treatment of cancer
🇨🇦
POINT Biopharma
$1.4B · Oct 2023
Cancer
Mablink Bioscience · Headquarters: France · Oct 2023 · Transforming cancer immunotherapy with next generation ADCs
🇫🇷
Mablink Bioscience
Oct 2023
Cancer
Aparito · Headquarters: United Kingdom · Jul 2024 · Platform digitizing clinical trials with patient-generated data
🇬🇧
Aparito
Jul 2024
Discovery & delivery
Morphic Therapeutic · Headquarters: United States · $3.2B · Jul 2024 · Biotechnology company developing a new generation of oral integrin therapies
🇺🇸
Morphic Therapeutic
$3.2B · Jul 2024
Immunology
Scorpion Therapeutics · Headquarters: United States · $2.5B · Jan 2025 · Acquisition of Scorpion’s STX-478 programme; the remaining company was spun out.
🇺🇸
Scorpion Therapeutics
$2.5B · Jan 2025
Cancer
SiteOne Therapeutics · Headquarters: United States · $1.0B · May 2025 · Developing novel therapeutics focused on the peripheral nervous system,
🇺🇸
SiteOne Therapeutics
$1.0B · May 2025
Neuroscience & sensory
Verve Therapeutics · Headquarters: United States · $1.3B · Jun 2025 · Focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary
🇺🇸
Verve Therapeutics
$1.3B · Jun 2025
Obesity & cardiometabolic
Adverum Biotechnologies · Headquarters: United States · Oct 2025 · Clinical stage gene therapy targeting unmet needs in ocular and rare diseases with durable therapeutic protein expression
🇺🇸
Adverum Biotechnologies
Oct 2025
Neuroscience & sensory
Ventyx Biosciences · Headquarters: United States · $1.2B · Jan 2026 · A biotechnology company with a diverse portfolio of best-in-class highly differentiated clinical and pre-clinical stage programs focused on high value targets
🇺🇸
Ventyx Biosciences
$1.2B · Jan 2026
Immunology
Orna Therapeutics · Headquarters: United States · $2.4B · Feb 2026 · Orna Therapeutics - Ahead of the Curve
🇺🇸
Orna Therapeutics
$2.4B · Feb 2026
Immunology
Centessa Pharmaceuticals · Headquarters: United States · $6.3B · Mar 2026 · Merger of ten pharmaceutical companies developing drugs for sleep-wake disorders, neurological conditions and cancer
🇺🇸
Centessa Pharmaceuticals
$6.3B · Mar 2026
Neuroscience & sensory
CrossBridge Bio · Headquarters: United States · $300M · Apr 2026 · Dual-payload antibody-drug conjugates to improve targeted cancer therapies and overcome tumor resistance
🇺🇸
CrossBridge Bio
$300M · Apr 2026
Cancer
Kelonia Therapeutics · Headquarters: United States · $3.3B · Apr 2026 · Developing a new wave of genetic medicines using its next generation vivo gene delivery platform
🇺🇸
Kelonia Therapeutics
$3.3B · Apr 2026
Cancer
Ajax Therapeutics · Headquarters: United States · $2.3B · Apr 2026 · Developing targeted therapies for hematologic cancers through innovative cytokine signaling pathways
🇺🇸
Ajax Therapeutics
$2.3B · Apr 2026
Cancer
Vaccine Company · Headquarters: United States · May 2026 · Next-generation nanoparticle vaccines for infectious diseases
🇺🇸
Vaccine Company
May 2026
Infectious disease
Engage Bio · Headquarters: United States · May 2026 · Transforms cancer cells into factories for immunotherapies
🇺🇸
Engage Bio
May 2026
Cancer
Curevo Vaccine · Headquarters: United States · May 2026 · Creating Next Generation Vaccines For Diseases Of Global Importance
🇺🇸
Curevo Vaccine
May 2026
Infectious disease
LimmaTech Biologics · Headquarters: Switzerland · May 2026 · Innovative vaccines combating antimicrobial resistance with proprietary multivalent technology
🇨🇭
LimmaTech Biologics
May 2026
Infectious disease
4E Therapeutics · Headquarters: United States · Jun 2026 · Innovative non-opioid therapies targeting chronic pain at its source
🇺🇸
4E Therapeutics
Jun 2026
Neuroscience & sensory
ATAI Life Sciences · Headquarters: Germany · $2.8B · Jul 2026 · A biotechnology company pioneering mental health innovation
🇩🇪
ATAI Life Sciences
$2.8B · Jul 2026
Neuroscience & sensory
Merida Biosciences · Headquarters: United States · $2.9B · Aug 2026 · Precision immunology leader developing targeted therapies for autoimmune and allergic disorders
🇺🇸
Merida Biosciences
$2.9B · Aug 2026
Immunology
Novo Nordisk
Corvidia · Headquarters: United States · $2.1B · Jun 2020 · Creating precision therapies by using the science of genomics in new ways
🇺🇸
Corvidia
$2.1B · Jun 2020
Obesity & cardiometabolic
EMISPHERE TECHNOLOGIES · Headquarters: United States · $1.4B · Nov 2020 · Innovative drug delivery solutions enhancing oral bioavailability of peptides, proteins, and large molecules
🇺🇸
EMISPHERE TECHNOLOGIES
$1.4B · Nov 2020
Discovery & delivery
Dicerna Pharmaceuticals · Headquarters: United States · $3.3B · Nov 2021 · Delivering RNAi-based breakthrough therapies to improve lives
🇺🇸
Dicerna Pharmaceuticals
$3.3B · Nov 2021
Discovery & delivery
Forma Therapeutics · Headquarters: United States · $1.1B · Sep 2022 · Improving the lives of people with diabetes and other chronic conditions
🇺🇸
Forma Therapeutics
$1.1B · Sep 2022
Rare blood disorders
Biocorp · Headquarters: France · $169M · Jun 2023 · Innovative medical devices for pharmaceutical companies
🇫🇷
Biocorp
$169M · Jun 2023
Discovery & delivery
Embark Biotech · Headquarters: Denmark · Aug 2023 · Novel therapeutics for obesity and metabolic diseases
🇩🇰
Embark Biotech
Aug 2023
Obesity & cardiometabolic
Inversago Pharma · Headquarters: Canada · $1.1B · Aug 2023 · Specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists
🇨🇦
Inversago Pharma
$1.1B · Aug 2023
Obesity & cardiometabolic
Cardior Pharmaceuticals · Headquarters: Germany · $1.1B · Mar 2024 · Non-coding RNA-based therapeutics in heart failure
🇩🇪
Cardior Pharmaceuticals
$1.1B · Mar 2024
Obesity & cardiometabolic
Akero Therapeutics · Headquarters: United States · $5.2B · Oct 2025 · Innovative therapies targeting metabolic liver disease
🇺🇸
Akero Therapeutics
$5.2B · Oct 2025
Obesity & cardiometabolic
Select an area to see its acquisitions.